# Lycopene's Role in Mitigating Obesity‐Induced Cardiac Remodeling: Insights Into Inflammatory and MMP‐2 Pathways

**Authors:** Carol Cristina Vagula de Almeida de Silva, Artur Junio Togneri Ferron, Fabiane Valentini Francisqueti‐Ferron, Alexandre Ribeiro da Silva, Silmeia Garcia Zanati Bazan, Jéssica Leite Garcia, Dijon Henrique Salomé de Campos, Mariane Róvero Costa, Daniele Dantas, Heloysa Amaral da Silva, Janaina Paixão das Chagas Silva, Giselle Pinto Faria de Lopes, Bertha Furlan Polegato, Camila Renata Correa, Fernando Moreto, Ana Lucia Anjos Ferreira

PMC · DOI: 10.1002/mnfr.70395 · 2026-01-26

## TL;DR

This study shows that lycopene can protect the heart from obesity-related damage by reducing inflammation and preventing collagen breakdown.

## Contribution

The study demonstrates lycopene's novel cardioprotective effects in obesity-induced cardiac remodeling through anti-inflammatory and MMP-2 inhibition mechanisms.

## Key findings

- Lycopene reversed insulin resistance and improved systolic and diastolic cardiac function in obese rats.
- Lycopene reduced inflammatory markers like TNF-α, IL-6, NF-κB, and TLR-4 in the heart.
- Lycopene inhibited MMP-2 activation and enhanced TIMP-2 and type I collagen expression, preserving myocardial structure.

## Abstract

Obesity, characterized by chronic low‐grade inflammation, promotes cardiac structural and functional abnormalities. This study evaluated the therapeutic potential of lycopene in attenuating obesity‐induced cardiac remodeling, based on its antioxidant and anti‐inflammatory properties and its ability to inhibit matrix metalloproteinase‐2 (MMP‐2) activation, thereby preserving myocardial collagen integrity. Male Wistar rats were fed a high‐sugar, high‐fat (HSF) diet to induce obesity and cardiac remodeling. After the onset of cardiac dysfunction, animals received lycopene supplementation (10 mg/kg/day) for 10 weeks. The HSF diet caused metabolic disturbances, including hypertension, increased adiposity, and insulin resistance, accompanied by myocardial remodeling, inflammation, and elevated MMP‐2 activity. Lycopene supplementation reversed insulin resistance, mitigated myocardial remodeling, and improved both systolic and diastolic cardiac function. It also reduced inflammatory markers (TNF‐α, IL‐6, NF‐κB, TLR‐4), decreased MMP‐2 activation, and enhanced TIMP‐2 and type I collagen expression. Lycopene demonstrated cardioprotective and anti‐inflammatory effects in obesity‐induced cardiac remodeling. By targeting inflammation and extracellular matrix degradation, lycopene may serve as an effective adjunctive therapeutic approach for preventing or treating obesity‐related cardiac disorders.

A. Consumption of a highsugar‐fat diet causes excess nutrients, hypertrophy and hyperplasia of adipocytes, causing obesity. Obesity leads to increased inflammatory levels in the heart, which stimulates greater activation of Metalloproteinase‐2 (MMP‐2), which has collagenolytic activity, degrading the collagen network in the heart, ultimately causing pathological cardiac remodeling, with systolic and diastolic dysfunction. B. Lycopene supplementation in obese individuals rat attenuates inflammation, MMP‐2 activity, and collagen degradation in the heart, and consequently cardiac remodeling, improving systolic and diastolic function.

## Linked entities

- **Proteins:** MMP2 (matrix metallopeptidase 2), TIMP2 (TIMP metallopeptidase inhibitor 2), TNF (tumor necrosis factor), IL6 (interleukin 6), NFKB1 (nuclear factor kappa B subunit 1), TLR4 (toll like receptor 4)
- **Chemicals:** lycopene (PubChem CID 446925)
- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** Mmp2 (matrix metallopeptidase 2) [NCBI Gene 81686], Timp2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 29543], Tlr4 (toll-like receptor 4) [NCBI Gene 29260], Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}
- **Diseases:** myocardial remodeling (MESH:D064752), insulin resistance (MESH:D007333), metabolic disturbances (MESH:D024821), cardiac structural and functional abnormalities (MESH:C566527), Inflammatory (MESH:D007249), cardiac disorders (MESH:D006331), adiposity (MESH:D018205), hypertension (MESH:D006973), Cardiac Remodeling (MESH:D020257), Obesity (MESH:D009765)
- **Chemicals:** sugar (MESH:D000073893), Lycopene (MESH:D000077276)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12835580/full.md

---
Source: https://tomesphere.com/paper/PMC12835580